Hong Kong IPO funds raised decreased by 17% from USD 51.6 billion in 2020 to USD 42.8 billion in 2021. Hong Kong’s IPOs accounted for 16% of the region’s IPOs with many enterprises viewing it as their first choice of fundraising platform in Asia and worldwide. Following market reforms in 2018, Hong Kong continues to grow its reputation as a global hub for biotech listings which allowed the listing of prerevenue biotech companies. Hong Kong hosted a further 20 companies listing under the “biotech” regime raising USD 4.8 billion in 2021.
Secondary listings are making Hong Kong an even more important capital-raising venue with a growing ecosystem for innovation and the new economy. Six US-listed Chinese companies have completed their secondary listings in Hong Kong and this trend is expected to continue into 2022. Please subscribe us to download full version of the article for further information.